Medical/Pharmaceuticals Global News & Press Release Distribution

Medical/Pharmaceuticals

All
APAC

111, Inc. Announces Change to Board of Directors

SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that Dr. Leon Lian ...

2024-11-04 18:00 1555

United Imaging Healthcare Announces Q3 2024 Results with Revenue of January to September of 6.95 Billion CNY

SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- United Imaging Healthcare (SSE: 688271), a global leader in manufacturing advanced medical imaging and radiotherapy equipment, announced its financial results for the third quarter of 2024. Reflecting its development strategy and strategic R&D investments, t...

2024-11-04 14:29 1135

Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services

HONG KONG and SHANGHAI, Nov. 2, 2024 /PRNewswire/ -- October 29, 2024, Ping An Healthcare Technology Co.,Ltd. successfully obtained the Digital Health Certificate (DHC) from the World Organization of Family Doctors (WONCA) and the WONCA Family Doctor Development & Enhancement (DEP) Certificate fo...

2024-11-03 01:39 2846

The clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved

SHENZHEN, China, Nov. 1, 2024 /PRNewswire/ -- On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., received the "Drug Clinical Trial Approval Notice" approved by th...

2024-11-01 19:04 2206

HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update

* HanAll records revenue of 36.8 billion KRW in the third quarter, with an operating profit of430 million KRW. * Results for the Phase 1 study in healthy subjects for HL192 (ATH-399A), a novel compound targeting Parkinson's Disease, are expected inNovember 2024. ROCKVILLE, Md. and SEOUL, Sout...

2024-11-01 19:00 2199

Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director

TAIPEI and SAN DIEGO, Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the appointment of Dr.Yiu-Lian Fong to the board of directors for Din...

2024-11-01 15:28 1440

PharmaResearch Hosts 5th Global Symposium on 'Rejuran'

* Over 600 Medical Professionals from 25 Countries Participate * Launch of 'IRC' Committee for Rejuran Global Research Team SEONGNAM, South Korea, Nov. 1, 2024 /PRNewswire/ -- PharmaResearch (CEO Ki Seock Kang and Thinkyou Kim) announced today that it successfully held the 5th PharmaResearch ...

2024-11-01 14:01 1532

PharmaResearch Hosts 5th Global Symposium on 'Rejuran'

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab

HONG KONG, Oct. 31, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, controlled, multicenter Phase III registration study for biliary track tumor. This trial is designed to comp...

2024-11-01 11:34 1417

CARsgen® U.S. Clinical Holds Lifted by FDA

SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration ("FDA") lifted the clinica...

2024-11-01 09:33 1430

Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain

TAIPEI, Oct. 31, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with DÁVI Farmacêutica ("DÁVI") inPortugal, for exclusive rights to the commercialization of clobetasol propionate oph...

2024-10-31 21:36 1554

The One-Year Outcome of LuX-Valve Plus TRAVEL II Study was Officially Released at TCT 2024

WASHINGTON, Oct. 31, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, has just released the 1-year outcome of LuX-Valve P...

2024-10-31 21:00 953

Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services

HONG KONG and SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) received the Digital Health Certification (DHC) and the Continuous Professional Development (CPD) certifications...

2024-10-31 20:14 1325

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

* Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs * Human-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancemen...

2024-10-31 20:00 990

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the ...

2024-10-31 19:00 1458

Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough

BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient's own immune cells to fight cancer. "Cancer often gains the upper hand by suppressing the imm...

2024-10-31 18:00 1102

ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)

* Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market * The availability of ZYMFENTRA will support greater patient access and choice while helping to drive greater affordabil...

2024-10-31 14:31 992

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC

CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") based on the positive results from the pivotal phase III OptiTROP-Lung04 study of sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) developed by Sichuan Kelun-Biotech Biopharmaceutical Co., L...

2024-10-31 12:02 1443

MGI's DNBSEQ-T20 x2 Selected As A Special Mention In TIME Best Inventions 2024

SHENZHEN, China, Oct. 30, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI") , a company committed to building core tools and technologies that drive innovation in life science, is thrilled to announce that its DNBSEQ-T20x2 Genetic Sequencer* has been recognized as a Specia...

2024-10-31 10:51 1311

MGI's DNBSEQ-T20 x2 Selected As A Special Mention In TIME Best Inventions 2024

Abionic's CAPSULE PSP Receives FDA Approval for Early Detection of Sepsis; Fapon Introduces Exclusive PSP Solution in China via Licensing Collaboration

DONGGUAN, China, Oct. 30, 2024 /PRNewswire/ -- Fapon, a global leading life sciences company, is thrilled to announce its PSP CLIA reagent solution which demonstrates promising outcomes in extensive clinical validation studies targeting Chinese population. Leveraging its strategic partnership ...

2024-10-31 10:26 1282

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab

HONG KONG, Oct. 30, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (AK117-302) for head and neck squamous cell carcinoma. This trial evaluates the innovative PD-1/VEGF bi...

2024-10-31 08:46 1925

1 234 5 6 ... 213